Boston Scientific: 3 Key Takeaways for Long-Term Investors

In its earnings call for the third quarter of 2026 on October 28, Boston Scientific (NYSE:BSX) revealed that a recent cyber incident, along with challenges in key product segments, is expected to hinder sales and earnings growth throughout 2027. For investors with a long-term perspective, this downturn presents a crucial test of the company's operational discipline and commitment to research, which are vital for restoring growth. Here are three major points discussed during the call that shed light on the current state of the business and its future prospects.

First, the company is facing significant operational disruptions and product-related challenges that are likely to keep its performance stagnant in 2027. An eight-day network outage has caused delays in shipments, while a decline in market share within the electrophysiology sector—focused on devices for heart rhythm disorders—and a decrease in left atrial appendage closure procedures have contributed to a broader decline in revenue. According to Michael F. Mahoney, the Chairman and CEO, these combined factors are expected to limit sales and profit growth for the upcoming year, excluding the effects of their pending acquisition of Penumbra. "As a result, we believe we will be challenged to grow sales and adjusted EPS in 2027," Mahoney stated.

Secondly, the company is undergoing a corporate restructuring aimed at enhancing operational efficiency and supporting long-term growth. To counteract the pressure on margins caused by changes in product mix and pricing issues in China, Boston Scientific's leadership is revamping supply chains and administrative functions. This cost-cutting initiative is designed to streamline corporate operations while ensuring that essential funding for research is maintained. Jonathan Monson, the Executive Vice President and CFO, noted, "We expect these efforts to deliver sustained cost efficiencies, while allowing us to prioritize investments that support long-term growth."

Lastly, management is focusing on its product pipelines and exploring new markets that could potentially yield $25 billion in opportunities by 2030. The company is making strides in pulsed-field ablation technologies—an innovative heart treatment method—and is expanding its cardiovascular platforms to regain commercial traction. Mahoney highlighted the significance of these investments, stating, "We have a very strong cadence of launches in 2027, 2028, and anticipate entering several new markets over the next few years that will lock $25 billion in new market opportunity by 2030."

Looking ahead, Boston Scientific is in the process of operational recovery as inventory levels stabilize and clinical trials in critical care areas bolster its core franchises. The management is focusing on high-unmet-need sectors, such as cardiogenic shock, which represents both a significant demand area and one where mechanical circulatory support can enhance patient outcomes. Dr. Ken Stein, Chief Medical Officer, emphasized this focus, stating, "This is both an area of major need and an area where we know that mechanical circulatory support can improve outcomes."